Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:20
|
作者
Weissfeld, JL
Fagerstrom, RM
O'Brien, B
机构
[1] NCI, Div Canc Prevent, Biometry Res Grp, Bethesda, MD 20892 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Westat Inc, Rockville, MD USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 06期
关键词
quality control; cancer screening; procedures; data analysis;
D O I
10.1016/S0197-2456(00)00094-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Investigators for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial describe quality control procedures for the digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, and flexible sigmoidoscopy. These cancer screening tests are subjective and difficult to standardize. PLCO quality control procedures aim to measure and, where possible, reduce variation, across examiner and screening center, with respect to cancer screening test performance. Initial protocols stressed examiner qualifications, experience, and training; equipment specifications; examination procedures; and definitions for positive tests. The PLCO quality assurance subcommittee developed a final quality assurance plan, which included central approval and registration of PLCO examiners, direct observation of screening test performance during periodic site visits by the National Cancer Institute and coordinating center auditors, periodic analysis of screening test data, and procedures for independently duplicating or reviewing selected examinations. For each modality, the periodic data analyses examine the test-positive and the test-inadequate proportions and aim to identify divergent centers or examiners. Procedures for duplicating examinations specify feasible sample sizes for precise estimates of agreement between examiners, at each center, for each screening test modality, and over a 1-year period. These quality control procedures will help characterize the consistency and reliability of the PLCO cancer screening tests. Control Clin Trials 2000;21:390S-399S (C) Elsevier Science Inc. 2000.
引用
收藏
页码:390S / 399S
页数:10
相关论文
共 50 条
  • [21] PROSTATE CANCER DETECTION WITH DIGITAL RECTAL EXAM IN THE PROSTATE LUNG COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Halpern, Joshua
    Shoag, Jonathan
    Mittel, Sameer
    Lipsitz, Stuart
    Ballman, Karla
    Hu, Jim
    JOURNAL OF UROLOGY, 2016, 195 (04): : E548 - E549
  • [22] Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Catherine A. McCarty
    Douglas J. Reding
    John Commins
    Craig Williams
    Meredith Yeager
    James K. Burmester
    Catherine Schairer
    Regina G. Ziegler
    Breast Cancer Research and Treatment, 2012, 133 : 785 - 792
  • [23] Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    McCarty, Catherine A.
    Reding, Douglas J.
    Commins, John
    Williams, Craig
    Yeager, Meredith
    Burmester, James K.
    Schairer, Catherine
    Ziegler, Regina G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (02) : 785 - 792
  • [24] Impact of PSA screening on mortality - PLCO Project Team (Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial)
    Heidenreich, A.
    Nitschmann, S.
    INTERNIST, 2010, 51 (02): : 219 - 220
  • [25] Flexible Sigmoidoscopy in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: Added Yield from a Second Screening Examination
    Weissfeld, Joel L.
    Schoen, Robert E.
    Pinsky, Paul F.
    Bresalier, Robert S.
    Doria-Rose, V. Paul
    Laiyemo, Adeyinka O.
    Church, Timothy
    Yokochi, Lance A.
    Yurgalevitch, Susan
    Rathmell, Joshua
    Andriole, Gerald L.
    Buys, Saundra
    Crawford, E. David
    Fouad, Mona
    Isaacs, Claudine
    Lamerato, Lois
    Reding, Douglas
    Prorok, Philip C.
    Berg, Christine D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (04): : 280 - 289
  • [26] Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
    Pinsky, Paul F.
    Parnes, Howard L.
    Andriole, Gerald
    BJU INTERNATIONAL, 2014, 113 (02) : 254 - 259
  • [27] Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Pinsky, Paul F.
    Blacka, Amanda
    Kramer, Barnett S.
    Miller, Anthony
    Prorok, Philip C.
    Berg, Christine
    CLINICAL TRIALS, 2010, 7 (04) : 303 - 311
  • [28] Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial
    Prorok, Philip C.
    Wright, Patrick
    Riley, Thomas R.
    Kramer, Barnett S.
    Berg, Christine D.
    Gohagan, John K.
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (04) : 257 - 273
  • [29] Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: Colorectal cancer survival by trial arm
    Doroudi, Maryam
    Pinsky, Paul F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Hayes, RB
    Reding, D
    Kopp, W
    Subar, AF
    Bhat, N
    Rothman, N
    Caporaso, N
    Ziegler, RG
    Johnson, CC
    Weissfeld, JL
    Hoover, RN
    Hartge, P
    Palace, C
    Gohagan, JK
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 349S - 355S